Studies have shown that patients who have already suffered from pulmonary inflammatory reactions, dermatitis, and hypothyroidism are most likely to develop multisystem irAEs.[16] While PD- L1 inhibitor combined with chemotherapy can reduce the overall incidence of irAEs.[17] Patients with advanced non-small cell lung cancer were treated with PD-L1 ICIs, and multisystem irAEs were associated with a better curative effect of immunotherapy.[18] In this case, the patient had no previous treatment history with other PD-L1 ICIs and the first simple chemotherapy was well tolerated. Here, CD274 is linked to skin disorder.